|
TOM1L1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.31050000243371E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.52930000008445E-07 |
| Normal-vs-Stage2 |
8.135600E-02 |
| Normal-vs-Stage3 |
4.04499989059559E-10 |
| Normal-vs-Stage4 |
1.46169999992729E-07 |
| Stage1-vs-Stage2 |
1.610050E-02 |
| Stage1-vs-Stage3 |
4.460300E-02 |
| Stage1-vs-Stage4 |
1.235400E-01 |
| Stage2-vs-Stage3 |
1.180380E-03 |
| Stage2-vs-Stage4 |
2.984900E-03 |
| Stage3-vs-Stage4 |
9.603200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.13790027084826E-10 |
| Normal-vs-AfricanAmerican |
1.238490E-02 |
| Normal-vs-Asian |
2.596100E-04 |
| Caucasian-vs-AfricanAmerican |
1.667840E-01 |
| Caucasian-vs-Asian |
3.167800E-01 |
| AfricanAmerican-vs-Asian |
5.916000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.82089999967161E-07 |
| Normal-vs-Female |
1.01849999989412E-07 |
| Male-vs-Female |
5.619600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.88550000004939E-06 |
| Normal-vs-Age(41-60Yrs) |
4.34669999993531E-07 |
| Normal-vs-Age(61-80Yrs) |
1.16669999994379E-07 |
| Normal-vs-Age(81-100Yrs) |
3.383100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.894200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.083800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.696600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.835800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.267400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.018200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.976300E-02 |
| Classical-VS-Follicular |
9.76029999999461E-05 |
| Classical-VS-Other |
9.523400E-01 |
| Classical-VS-Normal |
3.01459968099493E-10 |
| Tall-VS-Follicular |
1.13889999997507E-06 |
| Tall-VS-Other |
2.693000E-01 |
| Tall-VS-Normal |
1.67530000982907E-09 |
| Follicular-VS-Other |
2.270400E-01 |
| Follicular-VS-Normal |
1.384360E-01 |
| Other-VS-Normal |
2.564100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.2914000000045E-05 |
| Normal-vs-N1 |
1.73349999910144E-08 |
| N0-vs-N1 |
7.736900E-03 |
|
|
